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cense.Abstract Background:Bone marrow necrosis is a relatively rare entity which has been associated
with a poor prognosis. It is most commonly found in patients with neoplastic disorders and severe
infections.
Methods:The study comprised examination of 5043 bone marrow biopsy specimens performed at
the National Cancer Institute, Cairo University, over 7 years period (March 2004–March 2011).
It included 5 years retrospective (2867 archived samples) and 2 years prospective (2176 samples).
Results:Bone marrow necrosis was diagnosed in ﬁfteen out of 5043 examined specimens with a per-
centage of 0.3% and ranged from mild to massive according to semiquantitative estimation. Prog-
nosis of all patients was poor with survival not exceeding 6 months from the date of marrow
necrosis diagnosis.
Conclusion: In Egyptian patients, bone marrow necrosis in association with malignancy is a rare dis-
order which is accompanied by a poor outcome.
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Bone marrow necrosis (BMN) is a rare but serious ﬁnding in
various malignant and non malignant disorders. It is usually
a postmortem diagnosis. Bone marrow necrosis is regarded
as an uncommon entity that is associated with poor prognosis.
It was ﬁrst described in 1941 [1], and is deﬁned as necrosis of
myeloid tissue and medullary stroma in large areas of the mar-
row with preservation of the bone. The ﬁrst antemortum diag-
nosis was made in 1965 [2] in a patient with acute leukemia.
The pathophysiology of BMN has been a subject of contro-
versy and debate [3] and included toxic effect of chemotherapy,
microvascular infarction, and decreased oxygen tension due to
increased proliferative capacity of inﬁltrating malignant cells,
tumor necrosis factor and thrombosis [4].
Figure 1 Bone marrow biopsy (H/E) in a case of high grade
NHL showing massive necrosis with small areas of hemorrhage
(·40).
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examination, cells lose their normal staining pattern and have
irregular shape and margin on cytology [6]. It is usually
required to aspirate the marrow from multiple sites to obtain
enough material [7]. The combination of gelatinous transfor-
mation and necrosis is the hallmark of BM biopsy.
Patients and methods
Patients
Retrograde examination of bone marrow biopsy slides from
patients that were diagnosed and their slides were archived in
theHematologyUnit,Clinical PathologyDepartment,National
Cancer Institute, Cairo University, starting from April 2009
back to March 2004, searching for bone marrow necrosis, in
addition to the examination of newly received bone marrow
biopsy specimens until March 2011 for the same reason.
Bone marrow biopsy specimens were subjected to technical
methods applicable to trephine biopsy specimens, including ﬁx-
ation, decalciﬁcation and processing. After that, slides were
stained with hematoxylin and eosin [8]. We collected data of
the patients who showed BMN from their ﬁles. We recorded
their age, sex, symptoms, complaint at ﬁrst presentation, clinical
ﬁndings, diagnosis, and laboratory ﬁndings especially the levels
of alkaline phosphatase and lactate dehydrogenase enzymes.
We were able to examine 5043 slides of bone marrow
biopsy. BMN was graded semiquantitively [5] according to
the extent of necrosis in the bone marrow biopsy:
Grade I (mild): 620% of the biopsy.
Grade II (moderate –intermediate): 20–50% of the biopsy.
Grade III (severe-extensive): P50% of the biopsy.
The Olympus CH2 microscope was used for examination.
Photos were captured using a digital camera (Olympus C 30
40 ADU) connected to a microscope (Olympus CX 50) and
to a personal computer.
Results
The cases were as follows:
 A female patient, 32 years old. Examination of BM biopsy
revealed an intertrabicular area with complete inﬁlteration
with primitive looking cells (blasts), among which rare
mature neutrophilic series were seen and the remaining
two areas showed a combination of primitive and necrotic
cells. Examination of bone marrow aspirate showed com-
plete inﬁlteration (91%) of the marrow by blast cells, which
were myeloperoxidase (MPO) negative by cytochemical
stains, but which showed CD45, CD13 and CD56 positivity
by immunophenotyping. Also, immunohistochemistry done
on biopsy revealed CD56 positivity. A diagnosis of massive
bone marrow necrosis on top of myeloid/NK cell precursor
acute leukemia was made. The patient survived for
2 months after the biopsy was made.
 Massive marrow inﬁlteration by non hemopoietic malig-
nant sheets, together with massive bone marrow necrosis,
in a female patient aging 34 years and having medullary
carcinoma of the breast. The patient died 2 weeks after
the biopsy was taken. Primary bone marrow high grade non Hodgkin’s lym-
phoma, with no evidence of other areas of lymphoreticular
system involvement in a 58-years old male. Marrow
revealed massive necrosis (Fig. 1) and immunohistochemis-
try revealed B-cell markers. The patient survived for
5 months after the biopsy was taken.
 A case of Hodgkin’s disease in an 18-years old male patient.
He complained clinically of generalized lymphadenopathy,
splenomegaly, with no fever or night sweats. Marrow exam-
ination revealed mononuclear HD cells, which were CD30
positive by immunohistochemistry and a focus of bone mar-
row necrosis of less than 15% of the biopsy area (1/6 inter-
trabicular areas). The patient survived for 1 month after the
biopsy was taken.
 A 42-years old male with acute myeloid leukemia, hypocel-
lular on bone marrow aspirate examination, MPO positive
by cytochemistry, and myeloid phenotype by ﬂowcytome-
try. Karyotyping revealed normal karyotype (intermediate
grade). Diagnosed as AML-M1 FAB subtype. Moderate
BMN was detected (3/7 intertrabicular areas) and MPO
was positive by immunohistochemistry. The patient sur-
vived for 3 weeks after the biopsy was taken.
 A 56-years old male, diagnosed to have B-ALL by mor-
phology (L2) and immunophenotyping (CD19, CD10 posi-
tive). A focus of BMN as well as multiple small foci of
gelatinous marrow transformation were detected among a
bone marrow biopsy specimen totally inﬁlterated by blasts.
Immunohistochemistry revealed CD19 positivity. Cytoge-
netics showed hypodiploid karyotype. The patient survived
for 3 months after the biopsy was taken.
 A 47-years old female diagnosed to have diffuse large B cell
non Hodgkin’s lymphoma by lymph node biopsy. Bone
marrow aspirate showed 45% blasts. Immunophenotyping
revealed pan B, markers, CD5 and cytoplasmic IgM. Bone
marrow biopsy revealed many primitive cells among the
hemopoietic tissue, together with 2/6 bone marrow necrosis
area (moderate necrosis) (Fig. 2). The patient survived for
5 months after the biopsy was taken.
Figure 2 Bone marrow biopsy (H/E) in a case of diffuse large B
cell NHL showing primitive cells (blasts) with a small focus of
necrotic cells (·100).
Figure 3 Bone marrow biopsy (H/E) in a case of Hodgkin’s
disease showing massive necrosis with rare hemopoietic cells in
between (·40).
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phenotype, with 89% blasts in the bone marrow and B-cell
markers by ﬂowcytometry. Karyotyping showed t(1;19).
Mild BMN was detected, in the form of a small focus of
necrotic cells in 1/6 of intertrabicular areas. Immunohisto-
chemistry showed CD19 positivity and Lambda positivity.
The patient died 1 month after the biopsy was taken.
 A 52-years old male with advanced gastric cancer (poorly
differentiated adenocarcinoma) complaining of fever and
pancytopenia, bone marrow showed extensive bone marrow
necrosis and the patient died 16 days after admission.
 A 65-years old male with chronic myeloid leukemia was in
chronic phase for 6 years developed B cell lymphoblastic
crisis on top of CML, his marrow showed extensive necrosis
and symptomatic hypercalcemia. The patient died 2 days
after the biopsy was taken.
 A 35-years old female whose bone marrow biopsy showed
inﬁltration with reactive inﬂammatory back ground
together with Hodgkin cells and Reed Sternberg cells and
moderate BM necrosis. The patient took treatment for
3 weeks and she recovered the necrosis. One month later,
she presented clinically with fever, night sweating, cough-
ing, fatigue, shortness of breath and cervical lymphadenop-
athy and her CBC showed pancytopenia. Lymph nodes
ﬁnding showed inﬁltration with Hodgkin disease and the
patient died 1 month later.
 A 10-months old male diagnosed to have spindle cell sar-
coma. His B.M. was hypocellular for age with a small focus
of marrow necrosis (10% of total marrow area) and a small
area of grade II ﬁbrosis. At the time of biopsy, the patient
was on chemotherapy for 3 months. The patient died
3 months after the biopsy was taken.
 A 4-years old female diagnosed to have neuroblastoma, dis-
seminating to the marrow (stage IV). Her BM was hypocel-
lular for age with two small areas of marrow necrosis
(about 20% of total marrow area). At the time of biopsy,
the patient was on chemotherapy for 5 months. The patient
died 4 days after the biopsy was taken.
 A 2.5-years old female diagnosed to have de novo neuro-
blastoma disseminating to the marrow (Stage IV), withmassive BM necrosis. The patient died 3 days after the
biopsy was taken.
 A 26-years old female diagnosed to have de novo Hodgkin’s
disease nodular sclerosis type by lymph node biopsy. Exam-
ination of her BM biopsy revealed massive marrow necrosis
with rare hemopoietic cells seen. The patient died 3 weeks
after the biopsy was taken (Fig. 3).
As regards the most common complaints at presentation, 7
of the 15 patients had severe bone pains mostly in the lower
back and 9 complained of fever. Laboratory workup of the pa-
tients revealed pancytopenia in 9, leukoerythroblastic picture
in one and bicytopenia with leukocytosis in the other 5
patients. Serum lacate dehydrogenase and serum alkaline
phosphatase levels were elevated in all patients. Table 1 dem-
onstrates the prevalence of marrow necrosis within the differ-
ent disease entities.
Discussion
In the present study, we examined bone marrow biopsy slides
from 5043 patients presenting to the Hematology Unit in the
Clinical Pathology Department, National Cancer Institute,
Cairo University through a period of 7 years and detected 15
cases of bone marrow necrosis among them (0.3%). Bone mar-
row necrosis was ranging from mild to massive, according to
semiquantitative estimation [5]. Five patients suffered from so-
lid tumors (33.3%), while the other ten had hematologic malig-
nancies (66.6%). 13/15 (86.7%) patients were newly diagnosed,
while 2/15 were on chemotherapy (13.3%). All patients had
poor survival, not exceeding 6 months after the time the diag-
nosis of bone marrow necrosis was made.
The relative frequency of bone marrow necrosis varies
among different reports between 0.37% and 6.5% [3]. Given
the high rate of malignancy as an underlying disease associa-
tion, an extensive search for neoplastic disease is justiﬁed
whenever BMN is diagnosed [9].
Argon et al., reported that malignancy constitutes 91% of
the etiology of marrow necrosis, with hematologic malignancy
constituting 60% and solid tumors constituting 31%. A variety
Table 1 Prevalence of bone marrow necrosis in different disease entities.
Diagnosis Biopsies with necrosis (no/cases) Percentage (%)
Acute lymphocytic leukemia 2/228 0.88
Acute myelocytic leukemia 2/216 0.93
Hodgkin’s disease 3/1227 0.25
Non Hodgkin lymphoma 2/1473 0.14
Metastatic cancer
(of which two were on chemotherapy)
5/1683 0.30
Chronic myeloid leukemia 1*/198 0.51
Multiple myeloma 0/18 0
Total 15/5043 0.3
* A case of blastic crisis.
Table 2 Different disease entities in BMN with their relative frequency.
Reference Disease entities and their relative frequency
Number of cases ALL ANLL H.D. NHL CML Solid tumors Others
Present study 15 2 (13.3%) 2 (13.3%) 3 (20%) 2 (13.3%) 1 (6.7%) 5 (33.3%) –
Janssens et al. [6] 218 43 (19.7%) 55 (25.2%) 5 (2.3%) 26 (11.9%) 11 (5%) 72 (33%) 1ET 1MF
Paydas et al. [5] 16 1 (6.3%) 3 (18.8%) 4 (25%) 2 (12.5%) 2 (12.5%) 3 (18.8%) 1 MDS/MPN
Zhai et al. [11] 12 2 (16.7%) – – 1 (8.3%) 8 (66.6%) 1 Histiocytosis
ET, essential thrombocythemia; MF: myeloﬁbrosis; MDS/MPN; Myeloproliferative/myelodysplastic.
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BMN, most importantly, severe infections, drugs, sickle cell
disease and antiphospholipid syndrome [10]. In our study we
agree with Argon et al., in that 66.6% of our patients suffered
from hematologic malignancy, while only 33.3% suffered from
solid tumors as an underlying cause of BMN.
We also agree in our results with Dunn et al. [9], who stud-
ied 10,856 consecutive bone marrow aspirate and biopsy cases
through 13 years and reported 40 cases of BMN (0.37%), all
but two of whom had underlying malignancies. The most com-
mon underlying malignant disease was acute leukemia (8/38,
21%), followed by nasopharyngeal carcinoma and cancer of
unknown origin.
In our study, 2 of the 15 BMN cases were ALL (13.3%), 2
were AML (13.3%), 3 were H.D. (20%), 2 were NHL
(13.3%), 1 was CML (6.7%) and 5 were solid tumors
(33.3%). We agree in the relative frequency of the different
disease entities comprising the BMN with Paydas et al. and
the review article of Janssens et al. [5,6] as shown in Table
2. We disagree with Zhai et al. [11], who reports different rel-
ative frequencies concerning solid tumors (66.6%) and hema-
tologic malignancies (33.4%).
We also agree with some other authors who reported spo-
radic cases of BMN, concerning the prevalence of the disease
and the relative frequency of hematologic and solid tumors,
such as Pui and Stass [12], who received records of 1419 chil-
dren with acute leukemia and other malignant diseases involv-
ing the marrow and found 7 cases (0.49%), 5 of which were
ALL (71.4%) and 2 (28.6%) were neuroblastoma.
Several other authors reported BMN to be a rare entity,
such as Macfarlane and Tauro [13], who described 4 cases of
childhood ALL that developed BMN. Bevilacqua et al. [14],
and Niebrugge and Benjamin [15] described BMN which was
diagnosed ﬁrst, and eventually malignancy developed. Theformer described 7 cases of BMN; 6 proceeded to acute leuke-
mia and 1 to lymphoblastic lymphoma, and the latter de-
scribed 2 BMN cases that developed later ALL.
In Bone marrow necrosis, pancytopenia and embolic pro-
cesses are major complications, which are life threatening,
and that should be managed with supportive measures until
effective treatment of the underlying disease has been adminis-
tered [16].
When an underlying pathology was detected, vigorous sup-
portive care together with special treatment must be started
including transfusion of blood components, adequate antibi-
otic treatment, hydration, oxygenation and alkalinization to
permit a time for spontaneous recovery of the normal hemato-
poiesis. Given the complex pathophysiology of BMN [3,4],
some novel therapies such as anti tumor necrosis factor
(TNF)-a antibodies and various cytokines may be promising
modalities [10]. It has been suggested that therapy for patient
with BMN aims at promoting recovery of marrow stroma by
the use of cytokines and chemotherapy not highly toxic to
bone marrow stem cells and stroma [17]. Also, allogenic or
autologous bone marrow transplantation could be life saving
treatment strategies [18,19].
The ultimate prognosis in patients with BMN on top of a
malignant disorder is poor. In solid tumors, it implies wide-
spread metastasis and in hematologic malignancies, it aggra-
vates the condition and acute leukemia patients who suffer
from BMN, even though they might acquire complete remis-
sion, they ultimately relapse [20].
Conclusion
We conclude that in Egyptian patients, BMN in association
with malignancy is a rare disorder which is accompanied by
a poor outcome.
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